Pulmonary Hypertension

Pulmonary Arterial Hypertension Associated With CHD: Developments in Treatments, Remaining Gaps According to Experts

By

Tori Rodriguez, MA, LPC, AHC

PAH associated with CHD is linked to significant reductions in survival and quality of life, especially for patients progressing to Eisenmenger syndrome.

Pulmonary Hypertension With ILD: Diagnostic and Treatment Challenges

By

Tori Rodriguez, MA, LPC, AHC

Although pulmonary hypertension as a result of interstitial lung disease is linked to significant morbidity and mortality, there is no consensus regarding screening or management of the disease.

Thinking Outside the Lungs: Extrapulmonary Manifestations in PAH

By

Tori Rodriguez, MA, LPC, AHC

Emerging evidence suggests that the extrapulmonary effects of pulmonary arterial hypertension may manifest in the form of vascular dysfunction in systemic circulation, metabolic/endocrine dysfunction, and skeletal and respiratory muscle dysfunction.

ARROW Finds Selonsertib Ineffective for Pulmonary Arterial Hypertension

By

Virginia A. Schad, PharmD, RPh

Because oxidative stress and elevated ASK1 activity appear to play a role in vascular remodeling in PAH, ASK1 inhibition with selonsertib was studied.

Initial Triple vs Dual Oral Combination Therapy for Newly Diagnosed PAH

By

Jessica Nye, PhD

A study investigated the efficacy of double or triple pharmacotherapy in pulmonary arterial hypertension.

Presence of Pleural vs Pericardial Effusion in Patients With Pulmonary Hypertension

By

Sheila Jacobs

Researchers examined the link between pulmonary hemodynamic variables and the presence of pericardial and pleural effusion.

Precapillary Pulmonary Hypertension: Patient Characteristics and Prognosis

By

Bryant Moeller

Is the 2018 World Symposium on Pulmonary Hypertension definition of pre-capillary pulmonary hypertension beneficial in clinical practice?

Inhaled Imatinib Designated Orphan Drug for Pulmonary Arterial Hypertension

By

Brian Park, PharmD

AER-901 is an investigational drug-device combination therapy that consists of a nebulized formulation of imatinib and the Fox device, a breath-actuated smart nebulizer.

EmPHasis-10, CAMPHOR Reliably Assess HRQOL in New Pulmonary Hypertension

By

Brandon May

Health-related quality of life questionnaires created for pulmonary hypertension may be useful for clinicians in daily practice.

Cardiac Axis Deviation in Systemic Sclerosis-Related Pulmonary Hypertension

By

Pulmonology Advisor Contributing Writer

In patients with SSc-PH, RAD and LAD reflect structural cardiac abnormalities are associated with worse outcomes and increased risk for mortality.

CFTR Expression in the Pathogenesis of Pulmonary Arterial Hypertension

By

Virginia A. Schad, PharmD, RPh

Researchers sought to delineate the role of cystic fibrosis transmembrane conductance regulator (CFTR) in pulmonary arterial hypertension pathogenesis through observational and interventional experiments in human tissues and animal models.